-+ 0.00%
-+ 0.00%
-+ 0.00%

CULLINAN THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR CLN-049, A NOVEL FLT3XCD3 T CELL ENGAGER, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Reuters·05/19/2026 11:00:02

Please log in to view news